🔎 Trials Near Me

Utama › Kanser Ovari › Maryland

Kajian klinikal Kanser Ovari di Maryland

40 kajian untuk Kanser Ovari sedang mencari peserta di lokasi di Maryland.

Bandar di Maryland

Teks kajian rasmi (Bahasa Inggeris)

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

  • University of Maryland/Greenebaum Cancer Center, Baltimore
  • Walter Reed National Military Medical Center, Bethesda
  • National Institutes of Health Clinical Center, Bethesda
  • dan 1 lagi
Mengambil pesertaFasa 2
Semua umur · Semua jantina · Dikemas kini 2 Okt 2026 · NCT05564377

Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma

  • National Institutes of Health Clinical Center, Bethesda
Mengambil pesertaKajian pemerhatian
Umur 2 hingga 100 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT01950572

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

  • National Institutes of Health Clinical Center, Bethesda
Mengambil pesertaFasa 1
Umur 18 hingga 120 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06885697

Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis

  • National Institutes of Health Clinical Center, Bethesda
Mengambil pesertaKajian pemerhatian
Umur 3 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT01441089

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

  • National Institutes of Health Clinical Center, Bethesda
Mengambil pesertaFasa 2
Umur 18 hingga 72 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT01174121

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

  • Johns Hopkins University, Baltimore
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT06172478

Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer

  • Research Site, Baltimore
Mengambil pesertaFasa 3
Umur 18 ke atas · Wanita · Dikemas kini 1 Okt 2026 · NCT07851025

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

  • University of Maryland, Baltimore /ID# 275308, Baltimore
  • Holy Cross Hospital /ID# 275872, Silver Spring
Mengambil pesertaFasa 2
Umur 18 ke atas · Wanita · Dikemas kini 29 Sep 2026 · NCT06890338

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

  • National Institutes of Health Clinical Center, Bethesda
Mengambil pesertaFasa 2
Umur 18 hingga 72 · Semua jantina · Dikemas kini 28 Sep 2026 · NCT03412877

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

  • Greater Baltimore Medical Center, Baltimore
  • Sinai Hospital Of Baltimore, Baltimore
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07213804

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

  • United Theranostics, Glen Burnie
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07213791

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

  • Maryland Oncology Hematology (MOH) ( Site 8002), Columbia
Mengambil pesertaFasa 3
Umur 18 ke atas · Wanita · Dikemas kini 17 Sep 2026 · NCT07318558

A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

  • Greater Baltimore Medical Center, Baltimore
Mengambil pesertaFasa 2
Umur 18 hingga 99 · Wanita · Dikemas kini 15 Sep 2026 · NCT07023627

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

  • Holy Cross Hospital, Silver Spring
Mengambil pesertaFasa 3
Umur 18 ke atas · Wanita · Dikemas kini 15 Sep 2026 · NCT07214779

A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

  • Research Site, Baltimore
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 11 Sep 2026 · NCT05123482

The Vanguard Study: Testing a New Way to Screen for Cancer

  • Walter Reed National Military Medical Center, Bethesda
Mengambil pesertaSukarelawan sihat dialu-alukan
Umur 45 hingga 75 · Semua jantina · Dikemas kini 2 Sep 2026 · NCT06995898

Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

  • University of Maryland/Greenebaum Cancer Center, Baltimore
Mengambil pesertaFasa 2/3
Umur 18 ke atas · Semua jantina · Dikemas kini 19 Ogo 2026 · NCT07001748

Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers

  • National Institutes of Health Clinical Center, Bethesda
Mengambil pesertaFasa 1/2
Umur 18 hingga 72 · Semua jantina · Dikemas kini 13 Ogo 2026 · NCT02830724

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

  • Christiana Care - Union Hospital, Elkton
Mengambil peserta
Umur 35 hingga 50 · Wanita · Dikemas kini 7 Ogo 2026 · NCT04251052

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

  • Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
  • Christiana Care - Union Hospital, Elkton
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 7 Ogo 2026 · NCT06580314

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

  • USOR Maryland Oncology Hematology, Rockville
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 4 Ogo 2026 · NCT05579366

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

  • Maryland Oncology Hematology - Primary, Columbia
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Jul 2026 · NCT04657068

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

  • The John Hopkins Hospital, Baltimore
  • Maryland Oncology Hematology- Columbia, Rockville
Mengambil pesertaFasa 2
Umur 8 ke atas · Semua jantina · Dikemas kini 27 Jul 2026 · NCT05503797

Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)

  • University of Maryland, Baltimore
Mengambil pesertaFasa 3
Umur 18 ke atas · Wanita · Dikemas kini 14 Jul 2026 · NCT05804370

Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

  • Greater Baltimore Medical Center, Towson
Mengambil pesertaFasa 3
Umur 18 ke atas · Wanita · Dikemas kini 2 Jul 2026 · NCT06819007

EXoPERT EMERALD Clinical Study

  • John Hopkins University, Baltimore
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 45 ke atas · Semua jantina · Dikemas kini 1 Jul 2026 · NCT07186296

Integrated Cancer Repository for Cancer Research

  • Northwest Hospital, Randallstown
  • William E. Kahlert Regional Cancer Center, Westminster
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 19 hingga 110 · Semua jantina · Dikemas kini 29 Jun 2026 · NCT02012699

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

  • USA11-0, Bethesda
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Mei 2026 · NCT06953089

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

  • National Institutes of Health Clinical Center, Bethesda
Mengambil pesertaFasa 2
Umur 18 hingga 120 · Semua jantina · Dikemas kini 19 Mei 2026 · NCT06503146

Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers

  • Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 11 Mac 2026 · NCT03968406

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

  • Johns Hopkins - Sidney Kimmel Comprehensive Cancer Center, Baltimore
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 13 Feb 2026 · NCT06778863

CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

  • SCRI - Maryland Oncology Hematology, P.A., Annapolis
Mengambil pesertaFasa 2
Umur 18 ke atas · Wanita · Dikemas kini 23 Dis 2025 · NCT06690775

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Baltimore
  • Massive Bio SYNERGY-AI site, Bethesda
  • Massive Bio SYNERGY-AI site, Silver Spring
  • dan 1 lagi
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 28 Okt 2025 · NCT03452774

Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
Mengambil pesertaFasa 2
Umur 18 ke atas · Wanita · Dikemas kini 27 Okt 2025 · NCT06617923

Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer

  • Anne Arundel Health System, Annapolis
  • Johns Hopkins University School of Medicine, Baltimore
Mengambil pesertaKajian pemerhatian
Umur 30 ke atas · Wanita · Dikemas kini 16 Sep 2025 · NCT04794322

A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

  • Johns Hopkins, Baltimore
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Mei 2025 · NCT04503265

BP1001-A in Patients With Advanced or Recurrent Solid Tumors

  • Holy Cross Hospital, Silver Spring
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 7 Mac 2025 · NCT04196257

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.